Project CBD Newsletter: Psychedelic therapy for depression, psilocybin and dementia, CBD for lung cancer and neuropathic pain, and marijuana rescheduling
This week’s newsletter covers a promising psychedelic therapy pilot study for clinical depression, psilocybin research on dementia and childhood trauma, new findings on CBD for lung cancer and neuropathic pain, and a policy perspective on federal marijuana rescheduling.
Noteworthy Read
Psychedelic Therapy Standardized for Clinical Depression Shows Massive Promise (PsyPost)
A pilot trial of a standardized psychedelic therapy protocol for clinical depression reported significant symptom improvements, adding to interest in how structured treatment models may improve consistency across psychedelic studies. The results are encouraging, though larger controlled trials will be needed to separate drug effects, therapy effects, expectancy, and durability of benefit.
Read the full article
View more in Psychedelics
More Noteworthy Reading
Reclassifying Medical Marijuana Is Long Overdue, but It’s Not Enough (Daily Journal)
Paul Armentano argues that federal marijuana rescheduling would be a meaningful but incomplete reform, especially for patients, state-legal businesses, and people still affected by cannabis criminalization. He emphasizes the distinction between medical recognition under federal law and the broader policy changes needed to resolve banking, taxation, interstate commerce, and criminal justice issues.
Large Psilocybin Dose Improved Dementia in Case Study (MedicalNewsToday)
MedicalNewsToday reports on a case study in which a woman with advanced dementia showed apparent temporary improvement after receiving a large dose of psilocybin-containing mushrooms. The case is notable though limited in scope, highlighting the need for deeper research with a wider scope.
Read more
View more in Psychedelics
Taking Psychedelics at Raves May Help Childhood Trauma (PsyPost)
A new study reports that some people who used psychedelics in rave or ceremonial settings described reductions in trauma-related distress, including symptoms tied to childhood adversity. The findings raise questions about how context, social connection, music, and altered states may interact in trauma processing outside formal clinical settings.
Read more
View more in Psychedelics
Research Round-Up
Pros and Cons of Vaporized CBD for Neuropathic Pain (Journal of Cannabis Research)
A new paper examines vaporized CBD as a potential option for neuropathic pain, weighing its faster onset and flexible dosing against concerns around inhalation, product quality, and limited long-term safety data.
Clinical Trial: High-Dose CBD for Chronic Neuropathic Pain Associated With Spinal Cord Injury (EClinicalMedicine)
A clinical trial tested high-dose CBD in people with chronic neuropathic pain related to spinal cord injury, a condition that is often difficult to manage with standard medications. The study adds useful human data to the modern understanding of CBD’s therapeutic potential.
CBD Shows Potential Against Small Cell Lung Cancer (Marijuana Herald)
New research suggests CBD may have anticancer potential against small cell lung cancer through effects on tumor growth, cancer cell survival, and related molecular pathways. The findings are early-stage, but they add to ongoing research into cannabinoids as possible adjuncts or leads in cancer biology.
A heartfelt thank you to all of the CBD brands whose generous support enables Project CBD to bring you the latest in plant medicine research and journalism every week — we couldn’t do it without you.
The post Project CBD Newsletter: Psychedelic therapy for depression, psilocybin and dementia, CBD for lung cancer and neuropathic pain, and marijuana rescheduling appeared first on Project CBD.